Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.6% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 8.6% during trading on Monday . The stock traded as low as $22.09 and last traded at $21.63. 49,465 shares traded hands during trading, a decline of 80% from the average session volume of 242,814 shares. The stock had previously closed at $23.67.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DNTH shares. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and a consensus price target of $46.83.

Dianthus Therapeutics Trading Down 5.9 %

The firm has a market capitalization of $659.10 million, a P/E ratio of -8.88 and a beta of 1.72. The stock’s 50-day simple moving average is $22.89 and its 200-day simple moving average is $25.47.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of the business. Woodline Partners LP lifted its holdings in Dianthus Therapeutics by 20.0% during the fourth quarter. Woodline Partners LP now owns 300,504 shares of the company’s stock worth $6,551,000 after acquiring an additional 50,000 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after buying an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after buying an additional 363,500 shares during the last quarter. Millennium Management LLC grew its position in Dianthus Therapeutics by 160.2% during the fourth quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock valued at $1,972,000 after buying an additional 55,682 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Dianthus Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company’s stock worth $23,607,000 after buying an additional 136,314 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.